Diabetes drugs push Lilly's sales up, beating estimates

31 January 2017
lilly-logo-big

Eli Lilly (NYSE: LLY) presented financials this morning, showing that fourth-quarter 2016 revenue rose 7.2% to $5.76 billion, beating analysts' average estimate of $5.55 billion, helped by the strong performance of its diabetes drug franchise.

The US pharma major’s reported net income rocketed 61% to $771.8 million, or $0.73 per share. However, Lilly's non-generally accepted accounting principles (GAAP) earnings per share at $0.95 (up 22%) were below the $0.99 per share average analysts' expectations of nine analysts surveyed by Zacks Investment Research. on average.

Lilly’s shares were up 2.5% at $76.58 by late morning trading.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical